Valerio Del Bono
Overview
Explore the profile of Valerio Del Bono including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1526
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giacobbe D, Labate L, Russo Artimagnella C, Marelli C, Signori A, Di Pilato V, et al.
Infect Dis Ther
. 2024 Jul;
13(9):1929-1948.
PMID: 38995601
Introduction: Cefiderocol is a siderophore cephalosporin showing activity against various carbapenem-resistant Gram-negative bacteria (CR-GNB). No data currently exist about real-world use of cefiderocol in terms of types of therapy (e.g.,...
2.
Giacobbe D, Marelli C, Cattardico G, Fanelli C, Signori A, Di Meco G, et al.
J Antimicrob Chemother
. 2023 Aug;
78(10):2505-2514.
PMID: 37606528
Objectives: To assess the impact of carbapenem resistance on mortality in Klebsiella pneumoniae bloodstream infection (BSI) in the era of novel β-lactam/β-lactamase inhibitor combinations. Material And Methods: Retrospective study of...
3.
Gentile I, Buonomo A, Corcione S, Paradiso L, Giacobbe D, Bavaro D, et al.
Int J Antimicrob Agents
. 2023 Apr;
62(1):106817.
PMID: 37061102
Background: Ceftobiprole is approved in Europe for treatment of community-acquired pneumonia and non-ventilator-associated hospital-acquired pneumonia (HAP) in adults. Real-world data are limited. Methods: This multi-centre, observational, ambispective investigator-initiated study was...
4.
Vetrugno L, Castaldo N, Fantin A, Deana C, Cortegiani A, Longhini F, et al.
Pulmonology
. 2023 Jan;
29(6):457-468.
PMID: 36669936
Background: The risk of barotrauma associated with different types of ventilatory support is unclear in COVID-19 patients. The primary aim of this study was to evaluate the effect of the...
5.
De Rosa F, Palazzo A, Rosso T, Shbaklo N, Mussa M, Boglione L, et al.
J Clin Med
. 2021 Jun;
10(9).
PMID: 34062864
Background: CORACLE is a retrospective and prospective, regional multicenter registry, developed to evaluate risk factors for mortality in a cohort of patients admitted with SARS-CoV-2 infection within non-intensive wards. Methods:...
6.
Gianotti L, DAgnano S, Pettiti G, Tassone F, Giraudo G, Lauro C, et al.
AACE Clin Case Rep
. 2021 May;
7(5):288-292.
PMID: 33997278
Objective: During the ongoing coronavirus disease 2019 pandemic, procalcitonin (PCT) levels have proven useful in assisting clinicians to diagnose bacterial superinfection. However, in the absence of signs of infection or...
7.
Salvarani C, Dolci G, Massari M, Merlo D, Cavuto S, Savoldi L, et al.
JAMA Intern Med
. 2020 Oct;
181(1):24-31.
PMID: 33080005
Importance: The coronavirus disease 2019 (COVID-19) pandemic is threatening billions of people worldwide. Tocilizumab has shown promising results in retrospective studies in patients with COVID-19 pneumonia with a good safety...
8.
Giacobbe D, Salsano A, Del Puente F, Miette A, Vena A, Corcione S, et al.
Open Forum Infect Dis
. 2020 Aug;
7(8):ofaa233.
PMID: 32766378
Background: species are among the most frequent causative agents of health care-associated bloodstream infections, with mortality >40% in critically ill patients. Specific populations of critically ill patients may present peculiar...
9.
Mesini A, Mikulska M, Giacobbe D, Del Puente F, Gandolfo N, Codda G, et al.
Mycoses
. 2020 Jan;
63(4):361-368.
PMID: 31954083
Aim: During the last decade a continuous increase in non-albicans species isolation has been observed with Candida parapsilosis being one of the leading species. Aim of this study was to...
10.
Giacobbe D, De Rosa F, Del Bono V, Grossi P, Pea F, Petrosillo N, et al.
Expert Rev Anti Infect Ther
. 2019 Sep;
17(9):689-698.
PMID: 31553250
: Ceftobiprole is a fifth-generation cephalosporin with a broad spectrum of antimicrobial activity, including also methicillin-resistant (MRSA). Ceftobiprole is approved for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia...